Leflunomide use in New Zealand. A national prospective post-marketing study

Internal Medicine Journal

Volumn 39, Issue 2, 2009, Pages 95-102

  White, D H N ^a   Lynskey, N V ^a   Jones, P B B ^a,b  

^a QE Health   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cohort; Leflunomide; Post marketing

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DEXAMETHASONE; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE HEXACETONIDE; ISOXAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE PAIN; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; RESPIRATORY FUNCTION; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; FOLLOW UP; GASTROINTESTINAL DISEASES; MIDDLE AGED; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; REGISTER; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NEW ZEALAND; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; REGISTRIES; YOUNG ADULT;

EID: 63849254103     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01792.x     Document Type: Article

References (17)

1. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995 38 : 1595 603.
2. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999 353 : 259 66.
3. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999 159 : 2542 50.
4. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000 39 : 655 65.
5. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000 43 : 495 505.
6. Martin K, Bentaberry F, Dumoulin C, Dehais J, Haramburu F, Begaud B et al. Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials. Clin Exp Rheumatol 2005 23 : 80 4.
7. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3325 patients. Arthritis Rheum 2003 49 : 745 51.
8. Van Roon EN, Jansen TLTA, Mourad L, Houtman PM, Bruyn GAW, Griep EN et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004 58 : 201 8.
9. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003 62 : 944 51.
10. Pisoni L, Murgo A, Paresce E, Zeni S, Fantini F. Effectiveness and safety of leflunomide in the clinical practice. A different experience. Clin Exp Rheumatol 2007 25 : 115 19.
11. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002 41 : 421 30.
12. Prevoo M, van't Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 38 : 44 8.
13. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995 9 : 619 32.
14. Bettembourg-Brault I, Gossec L, Pham T, Gottenberg JE, Damiano J, Dougados M. Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs. Clin Exp Rheumatol 2006 24 : 168 71.
15. Chan V, Tett SE. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf 2006 15 : 485 93.
16. Jakez-Ocampo J, Richaud-Patin Y, Simon JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 2002 69 : 307 11.
17. Jaimes-Hernandez J, Robles-San Roman M, Suarez-Otero R, Davalos-Zugasti ME, Arroyo-Borrego S. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. J Rheumatol 2004 31 : 235 7.